SERUM INSTITUTE OF INDIA chief executive officer Adar Poonawalla said he is trying to resolve the issues faced by Indians vaccinated with Covishield while traveling to the European Union (EU).
He hoped to resolve the matter soon, having raised it at the highest level.
Covishield is the Oxford University-AstraZeneca vaccine manufactured in India by the Pune-based vaccine major.
"I realise that a lot of Indians who have taken Covishield are facing issues with travel to the EU, I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said in a tweet on Monday (28).
According to report, Covishield, the AstraZeneca-Oxford vaccine manufactured by the Serum Institute of India, is yet to get recognition from the European Medicines Agency (EMA).
EMA is responsible for the evaluation and supervision of medicinal products in the region.
At present, EU recognises Vaxzevria (previously Covid-19 vaccine AstraZeneca, Oxford).
The other vaccines approved by the agency are Comirnaty by BioNTech-Pfizer, Moderna and Janssen (Johnson & Johnson).
Serum Institute of India has produced more than 100 million doses of Covishield vaccine in June so far. This is in line with India’s efforts to increase the pace of its vaccination drive.
